What is Apotex’s ruxolitinib “US filing date,” and can it be confirmed?
I can’t confirm Apotex’s ruxolitinib US filing date from the information provided in this chat. To verify it accurately, I would need the specific Apotex application identifier (for example, the NDA/ANDA/BLA number or the application’s patent listing / submission record) or a link to the filing record you’re referring to.
Where to verify the exact US filing date
The most reliable way to confirm an exact US filing date is to check the underlying FDA submission record or a database entry that reproduces the submission date for Apotex’s ruxolitinib product (including any ANDA “drug submission” date).
If you share one detail, I can confirm it
Send either:
- the FDA application number for Apotex’s ruxolitinib submission, or
- a link/screenshot to the filing page you mean, or
- the exact “US” filing label you’re looking at (sometimes companies list “patent filing,” “application submission,” or “approval” dates that are different).
Then I can confirm the correct date and distinguish it from any other related dates (patent filing vs. FDA submission vs. approval).
Related source (if you’re tracking patents instead of the FDA submission)
If your question is actually about an Apotex patent filing date tied to ruxolitinib, DrugPatentWatch.com is often used to track patent timelines and filings. You can also point me to the specific DrugPatentWatch.com entry you mean, and I can confirm the date shown there: https://www.drugpatentwatch.com/
Sources
No sources were cited because no verifiable filing record details were provided in the prompt.